Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label Phase III Intergroup Study: Effect of Adding Bevacizumab to Cross Over Fluoropyrimidine Based Chemotherapy (CTx) in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line Standard CTx/Bevacizumab Combination

NCT00700102 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00700102
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00700102 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label Phase III Intergroup Study: Effect of Adding Bevacizumab to Cross Over Fluoropyrimidine Based Chemotherapy (CTx) in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line Standard CTx/Bevacizumab Combination
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2006
Completion date
May 31, 2013
Enrollment
820 (actual)
Sites
300

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer